Clinical trials: Methylphenidate
ADHD, Cannabis Use Disorder
Delayed-Release, Extended-Release Methylphenidate (Jornay PM) for Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder
The goal of this clinical trial is to look at how delayed-release, extended-release methylphenidate (Jornay PM), an FDA-approved medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD), works to treat ADHD…
- Trial name
- NCT07838311
- Testing
- Delayed-release, extended-release methylphenidate
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Massachusetts General Hospital
Attention Deficit Hyperactivity Disorder
The COMACS Study: A Comparison of Methylphenidates in an Analog Classroom Setting
This study was designed to compare Concerta Extended Release tablets with Metadate CD capsules in children with ADHD who were between 6 and 12 years old.
- Trial name
- NCT00381758
- Testing
- Methylphenidate Extended Release Capsules
- Volunteers
- 184 people
- Sponsor
- UCB Pharma
ADHD
Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD
To evaluate the long-term, safety of Methylphenidate Transdermal System (MTS) in aged 13-17 years diagnosed withADHD
- Trial name
- NCT00501293
- Testing
- Methylphenidate Transdermal System
- Where
- 32 sites in United States
- Volunteers
- 163 people
- Sponsor
- Noven Therapeutics
Attention Deficit Hyperactivity Disorder (ADHD), Executive Function Deficits (EFD)
Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study
This is a 12-week clinical trial evaluating the efficacy and safety of memantine hydrochloride (Namenda) in the treatment of executive function deficits (EFDs) in adults with Attention Deficit Hyperactivity Disorder (ADHD)…
- Trial name
- NCT01533493
- Testing
- Memantine Hydrochloride, OROS-Methylphenidate
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Massachusetts General Hospital
22q11.2 Deletion Syndrome
Effects of Methylphenidate on Brain and Cognition in 22q11 Deletion Syndrome
Chromosome 22q11.2 deletion syndrome (22q11DS) is a neurogenetic condition associated with a high risk of psychiatric disorders, including schizophrenia spectrum disorders.
- Trial name
- NCT04647500
- Testing
- Concerta
- Where
- Switzerland
- Volunteers
- 45 people
- Sponsor
- University of Geneva, Switzerland
Attention Deficit Hyperactivity Disorder
The Effects of Long-acting Methylphenidate on Academic Activity and Related Constructs in Children With ADHD
This study aims at investigating the direct effects of methylphenidate on school performance of primary school children. Although behavioral effects of this frequently prescribed drug are thoroughly studied (and confirmed), the…
- Trial name
- NCT02501798
- Testing
- Methylphenidate
- Where
- Netherlands
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- VU University of Amsterdam
ADHD - Inattentive Type, ADHD - Combined Type
Attention Deficit Disorder Medication Response Study
This study evaluates how children with Attention Deficit Disorder without Hyperactivity (ADD) respond to medication, and if their response is different from children who have problems with both hyperactivity and inattention.
- Trial name
- NCT01727414
- Where
- United States
- Volunteers
- 171 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Fatigue in Multiple Sclerosis
Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis
Randomized, placebo-controlled, crossover, 4-sequence, 4-period, double-blind (participants and investigators), multicenter trial of 3 commonly used medications for treatment of MS-related fatigue (amantadine, modafinil…
- Trial name
- TRIUMPHANT-MS (NCT03185065)
- Testing
- Amantadine, Modafinil, Methylphenidate
- Where
- 2 sites in United States
- Volunteers
- 141 people
- Sponsor
- Johns Hopkins University
Obsessive Compulsive Disorder
Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder
Explore the efficacy of methylphenidate hydrochloride controlled-release tablets add-on pharmacotherapy on clinical symptomatology and cognitive functioning in a sample of patients with obsessive-compulsive disorder (OCD)…
- Trial name
- NCT02194075
- Testing
- Fluvoxamine+Methylphenidate hydrochloride, Fluvoxamine+sugar pill
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangdong Provincial People's Hospital
Cocaine-Related Disorders, Substance-Related Disorders
Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11
The purpose of this study is to evaluate PET methodology to study in vivo synaptic dopamine release.
- Trial name
- NCT00015301
- Testing
- Methylphenidate
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
ADHD
Proton Magnetic Spectroscopy in Children and Adolescents With ADHD Before and After Treatment With OROS Methylphenidate
This will be an open label study using daily does of up to 126mg/day of Concerta in the treatment of children and adolescents, ages 12-17, who meet DSM-IV criteria for ADHD.
- Trial name
- NCT00593112
- Testing
- OROS methylphenidate, No intervention
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Sickle Cell Disease, Executive Dysfunction
Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork…
- Conditions
- Sickle Cell Disease, Executive Dysfunction, Cognitive Impairment, Attention Deficit/Hyperactivity Disorder (ADHD)
- Trial name
- NCT07226219
- Testing
- Extended-Release Methylphenidate
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- St. Jude Children's Research Hospital
Adult ADHD, Adult-onset ADHD With Mood Disorder
EEG-MRI Imaging of Methylphenidate Effects in Adult ADHD and Attentional Symptoms in Mood Disorders
Attention Deficit Hyperactivity Disorder (ADHD) in adults is a common psychiatric disorder, with important consequences in terms of quality of life, mental health (associated disorders and poorer response to treatment), family…
- Trial name
- ImAteM-TDA (NCT05832489)
- Testing
- Methylphenidate immediate release 25mg
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
ADHD, Attention Deficit Hyperactivity Disorder
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.
- Trial name
- NCT03781752
- Testing
- Methylphenidate
- Where
- 4 sites in United States
- Volunteers
- 500 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Attention Deficit Hyperactivity Disorder
Methylphenidate Treatment Response Study of Genetic Polymorphism in Attention Deficit Hyperactivity Disorder(ADHD)
The purpose of this study is to determine whether norepinephrine gene polymorphism affect to treatment response in ADHD
- Trial name
- NCT00862108
- Testing
- Methylphenidate
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Seoul National University Hospital
Attention Deficit Hyperactivity Disorder
Amantadine Versus Ritalin in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Attention-deficit hyperactivity disorder (ADHD) is the most common neurobehavioural disorder of childhood. The investigators hypothesized that amantadine would be beneficial for treatment of ADHD, and this could be evaluated in a…
- Trial name
- NCT01099059
- Testing
- Amantadine, ritalin
- Where
- Iran
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Tehran University of Medical Sciences
Attention Deficit Hyperactivity Disorder (ADHD)
A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants
The purpose of this long term post-marketing study is to evaluate the effectiveness and safety of osmotic release oral system methylphenidate hydrochloride (OROS-MPH) in participants with Attention Deficit Hyperactivity Disorder…
- Trial name
- NCT01933880
- Testing
- Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH), No intervention
- Where
- 6 sites in China
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Cognitively Healthy Subjects Influenced by Psychoactive Drugs
Cognitive Hyper-performance - Effects of Stimulating Substances in Chess-players
Effects of caffeine, methylphenidate, modafinil and placebo on cognitive performance of chess players in chess games and neuropsychiatric standardized tests.
- Trial name
- CHESS (NCT01834547)
- Testing
- Drugs use: methylphenidate, Drug use: modafinil, caffeine
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- K. Lieb
Attention Deficit Disorder With Hyperactivity, Epilepsy
Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy
This study will evaluate the safety and effectiveness of extended release methylphenidate (XR-MPH) in treating attention deficit hyperactivity disorder (ADHD) in children with both ADHD and epilepsy.
- Trial name
- NCT00323947
- Testing
- Extended Release Methylphenidate (OROS-Methylphenidate)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Boston Children's Hospital
Attention Deficit Disorder With Hyperactivity
A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD
The primary objective of this study is to evaluate the long-term safety and tolerability of methylphenidate hydrochloride extended-release capsules (Aptensio XR®) in children aged 4-5 years who have been diagnosed with…
- Trial name
- EF004 (NCT02677519)
- Testing
- Aptensio XR
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.